Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
12
2020
accepted:
16
02
2021
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
13
10
2021
Statut:
epublish
Résumé
Early detection of hepatocellular carcinoma (HCC), the most common primary liver malignancy, is crucial to offer patients a potentially curative treatment strategy such as surgical resection or liver transplantation (LT). However, easily accessible biomarkers facilitating an early diagnosis of HCC as well as a reliable risk prediction are currently missing. The microRNA(miR)-107 has recently been described as a driver of HCC in both murine and human HCC but data on circulating miR-107 in HCC patients are scarce. In the present study, we evaluated a potential diagnostic and/or prognostic role of circulating miR-107 in patients undergoing tumor resection or LT for early-stage HCC. The Kmplot bioinformatic tool was used to query publicly available databases (including TCGA, GEO and EGA) in order to analyse the prognostic value of tumoral miR-107 expression in HCC patients (n = 372). Serum levels of miR-107 were measured by qPCR in n = 45 HCC patients undergoing surgical tumor resection (n = 37) or LT (n = 8) as well as n = 18 healthy control samples. Results were correlated with clinical data. A high tumoral expression of miR-107 was associated with a significantly better overall survival compared to patients with low miR-107 expression levels (HR 0.69, 95% CI 0.48-0.99, p = 0.041). In addition, serum levels of miR-107 were significantly higher in HCC patients when compared to healthy controls. However, miR-107 serum levels in HCC patients were independent of different disease etiology, tumor stage or tumor grading. HCC patients with baseline miR-107 expression levels above a calculated ideal prognostic cut-off value (9.82) showed a clear trend towards an impaired overall survival (p = 0.119). Tumoral miR-107 expression levels are a potential prognostic marker in early stage HCC. Furthermore, we describe a potential role of circulating miR-107 levels as a diagnostic biomarker in patients with early-stage HCC.
Sections du résumé
BACKGROUND
Early detection of hepatocellular carcinoma (HCC), the most common primary liver malignancy, is crucial to offer patients a potentially curative treatment strategy such as surgical resection or liver transplantation (LT). However, easily accessible biomarkers facilitating an early diagnosis of HCC as well as a reliable risk prediction are currently missing. The microRNA(miR)-107 has recently been described as a driver of HCC in both murine and human HCC but data on circulating miR-107 in HCC patients are scarce. In the present study, we evaluated a potential diagnostic and/or prognostic role of circulating miR-107 in patients undergoing tumor resection or LT for early-stage HCC.
METHODS
The Kmplot bioinformatic tool was used to query publicly available databases (including TCGA, GEO and EGA) in order to analyse the prognostic value of tumoral miR-107 expression in HCC patients (n = 372). Serum levels of miR-107 were measured by qPCR in n = 45 HCC patients undergoing surgical tumor resection (n = 37) or LT (n = 8) as well as n = 18 healthy control samples. Results were correlated with clinical data.
RESULTS
A high tumoral expression of miR-107 was associated with a significantly better overall survival compared to patients with low miR-107 expression levels (HR 0.69, 95% CI 0.48-0.99, p = 0.041). In addition, serum levels of miR-107 were significantly higher in HCC patients when compared to healthy controls. However, miR-107 serum levels in HCC patients were independent of different disease etiology, tumor stage or tumor grading. HCC patients with baseline miR-107 expression levels above a calculated ideal prognostic cut-off value (9.82) showed a clear trend towards an impaired overall survival (p = 0.119).
CONCLUSION
Tumoral miR-107 expression levels are a potential prognostic marker in early stage HCC. Furthermore, we describe a potential role of circulating miR-107 levels as a diagnostic biomarker in patients with early-stage HCC.
Identifiants
pubmed: 33711036
doi: 10.1371/journal.pone.0247917
pii: PONE-D-20-40376
pmc: PMC7954311
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating MicroRNA
0
MIRN107 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247917Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Mol Sci. 2020 Nov 07;21(21):
pubmed: 33171811
Clin Biochem. 2019 Mar;65:45-52
pubmed: 30653948
Innovation (N Y). 2020 Aug 28;1(2):100032
pubmed: 32914142
Oncol Rep. 2014 Apr;31(4):1699-706
pubmed: 24549282
Arch Toxicol. 2018 Jan;92(1):83-119
pubmed: 29197930
Nature. 2011 Jun 08;474(7353):649-53
pubmed: 21654750
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
Int J Mol Sci. 2018 Jan 16;19(1):
pubmed: 29337905
Cancer Biomark. 2017;18(2):209-214
pubmed: 27983537
J Mol Med (Berl). 2005 Oct;83(10):774-85
pubmed: 15976920
World J Hepatol. 2017 Apr 28;9(12):586-594
pubmed: 28515844
Tumour Biol. 2015 Sep;36(10):7439-47
pubmed: 25903466
Clin Exp Hepatol. 2020 Sep;6(3):170-175
pubmed: 33145423
Mol Nutr Food Res. 2015 Mar;59(3):552-65
pubmed: 25522185
Noncoding RNA. 2020 Aug 29;6(3):
pubmed: 32872482
Oncol Lett. 2018 Apr;15(4):4097-4104
pubmed: 29541175
Gastroenterology. 2018 Dec;155(6):1951-1966.e26
pubmed: 30165047
Cancer Biol Ther. 2018 May 4;19(5):400-406
pubmed: 29333940
Clin Gastroenterol Hepatol. 2020 Mar;18(3):728-735.e4
pubmed: 31712073
Gastroenterology. 2018 Oct;155(4):1128-1139.e6
pubmed: 29981779
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Medicine (Baltimore). 2017 Jan;96(2):e5642
pubmed: 28079796
World J Gastroenterol. 2015 Oct 7;21(37):10573-83
pubmed: 26457017
Gastroenterology. 2018 May;154(6):1706-1718.e1
pubmed: 29425931
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Virus Res. 2018 Aug 15;255:77-84
pubmed: 30003924
PLoS One. 2020 Sep 22;15(9):e0239386
pubmed: 32960907
Oncol Lett. 2018 Apr;15(4):4571-4577
pubmed: 29541227
Nat Rev Genet. 2016 Dec;17(12):719-732
pubmed: 27795564